IN2014DN06522A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN06522A IN2014DN06522A IN6522DEN2014A IN2014DN06522A IN 2014DN06522 A IN2014DN06522 A IN 2014DN06522A IN 6522DEN2014 A IN6522DEN2014 A IN 6522DEN2014A IN 2014DN06522 A IN2014DN06522 A IN 2014DN06522A
- Authority
- IN
- India
- Prior art keywords
- car
- domain
- signaling domain
- alter
- administering
- Prior art date
Links
- 230000011664 signaling Effects 0.000 abstract 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000016396 cytokine production Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/464468—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70507—CD2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/21—Transmembrane domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261601907P | 2012-02-22 | 2012-02-22 | |
PCT/US2013/027361 WO2013126729A1 (en) | 2012-02-22 | 2013-02-22 | Use of the cd2 signaling domain in second-generation chimeric antigen receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN06522A true IN2014DN06522A (el) | 2015-06-12 |
Family
ID=49006248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN6522DEN2014 IN2014DN06522A (el) | 2012-02-22 | 2013-02-22 |
Country Status (15)
Country | Link |
---|---|
US (5) | US9783591B2 (el) |
EP (2) | EP2817331B1 (el) |
JP (1) | JP2015509716A (el) |
KR (1) | KR20140127829A (el) |
CN (1) | CN104136458A (el) |
AU (1) | AU2013222284A1 (el) |
BR (1) | BR112014020502A2 (el) |
CA (1) | CA2864489C (el) |
EA (1) | EA201491573A1 (el) |
ES (1) | ES2959443T3 (el) |
IL (1) | IL233993A0 (el) |
IN (1) | IN2014DN06522A (el) |
MX (1) | MX2014010185A (el) |
SG (1) | SG11201404284SA (el) |
WO (1) | WO2013126729A1 (el) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2014DN06522A (el) * | 2012-02-22 | 2015-06-12 | Univ Pennsylvania | |
TW201446794A (zh) | 2013-02-20 | 2014-12-16 | Novartis Ag | 利用抗-cd123嵌合抗原受體工程化t細胞之初級人類白血病有效靶向 |
WO2014130657A1 (en) | 2013-02-20 | 2014-08-28 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
WO2014145252A2 (en) | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
BR112016013187A2 (pt) | 2013-12-19 | 2017-09-26 | Novartis Ag | receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos |
WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
EP4303229A3 (en) | 2014-01-21 | 2024-04-17 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
AU2015244039B2 (en) | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
WO2015179801A1 (en) * | 2014-05-23 | 2015-11-26 | University Of Florida Research Foundation, Inc. | Car based immunotherapy |
US10568947B2 (en) | 2014-07-21 | 2020-02-25 | Novartis Ag | Treatment of cancer using a CLL-1 chimeric antigen receptor |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
CA2955154C (en) | 2014-07-21 | 2023-10-31 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
SG11201700476VA (en) | 2014-07-21 | 2017-02-27 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
WO2016028896A1 (en) | 2014-08-19 | 2016-02-25 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
KR102615681B1 (ko) | 2014-08-28 | 2023-12-18 | 바이오아트라, 인코퍼레이티드 | 변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체 |
JP6839074B2 (ja) | 2014-09-17 | 2021-03-03 | ノバルティス アーゲー | 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング |
EP3204777B1 (en) | 2014-10-08 | 2024-06-12 | Novartis AG | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
CA2962375C (en) | 2014-10-09 | 2020-07-14 | Yamaguchi University | Car expression vector and car-expressing t cells |
EP4036109A3 (en) | 2014-12-29 | 2022-10-12 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
WO2016115482A1 (en) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
CA2973524A1 (en) | 2015-01-26 | 2016-08-04 | Cellectis | Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy |
CA2975384A1 (en) | 2015-01-29 | 2016-08-04 | Regents Of The University Of Minnesota | Chimeric antigen receptors, compositions, and methods |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
EP3256492A4 (en) | 2015-02-09 | 2018-07-11 | University of Florida Research Foundation, Inc. | Bi-specific chimeric antigen receptor and uses thereof |
WO2016134284A1 (en) | 2015-02-19 | 2016-08-25 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
ES2923894T3 (es) | 2015-04-08 | 2022-10-03 | Novartis Ag | Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina |
ES2948133T3 (es) | 2015-04-17 | 2023-08-31 | Novartis Ag | Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico |
CN105198790B (zh) * | 2015-04-20 | 2018-02-16 | 范国煌 | 促进双阴性t细胞体外增殖的四环化合物 |
PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
US11370845B2 (en) | 2015-06-24 | 2022-06-28 | Keio University | Anti-glypican-1-immunizing antigen receptor |
US11116795B2 (en) | 2015-07-10 | 2021-09-14 | The Trustees Of The University Of Pennsylvania | Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor |
AR105433A1 (es) | 2015-07-21 | 2017-10-04 | Novartis Ag | Métodos para mejorar la eficacia y expansión de las células inmunes |
GB201513540D0 (en) | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
US11890301B2 (en) | 2015-08-28 | 2024-02-06 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
EP3340998B1 (en) * | 2015-08-28 | 2023-01-11 | The Trustees of the University of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
MA44314A (fr) * | 2015-11-05 | 2018-09-12 | Juno Therapeutics Inc | Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées |
JP2018536436A (ja) | 2015-12-04 | 2018-12-13 | ノバルティス アーゲー | 免疫腫瘍学のための組成物および方法 |
WO2017112741A1 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
CN110699371A (zh) * | 2016-03-18 | 2020-01-17 | 江苏普瑞康生物医药科技有限公司 | 一种基于FcγRⅢa的嵌合基因及其用途 |
EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
EP3988111A1 (en) * | 2016-04-01 | 2022-04-27 | Innovative Cellular Therapeutics Holdings, Ltd. | Use of chimeric antigen receptor modified cells to treat cancer |
US11634498B2 (en) | 2016-04-29 | 2023-04-25 | University Of Florida Research Foundation, Incorporated | Chimeric antigen receptors and uses thereof |
IL262404B2 (en) | 2016-05-13 | 2024-04-01 | Bioatla Llc | Antibodies, Antibody Fragments and Their Immunomodules Against ROR2 and Their Uses |
CN109715668A (zh) | 2016-08-02 | 2019-05-03 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重编程的组合物和方法 |
CN108699163B (zh) * | 2016-09-28 | 2021-11-19 | 阿思科力(苏州)生物科技有限公司 | 一种多基因重组嵌合抗原受体分子及其应用 |
ES2875959T3 (es) | 2016-10-07 | 2021-11-11 | Tcr2 Therapeutics Inc | Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión |
JP7467117B2 (ja) | 2016-10-07 | 2024-04-15 | ノバルティス アーゲー | 癌の治療のためのキメラ抗原受容体 |
US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
CN106754725A (zh) * | 2016-12-26 | 2017-05-31 | 北京普瑞金科技有限公司 | 一种嵌合抗原受体t细胞及其制备方法与应用 |
EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Car t細胞療法のための組成物および方法 |
EA201992232A1 (ru) | 2017-03-22 | 2020-05-14 | Новартис Аг | Композиции и способы для иммуноонкологии |
KR20240059648A (ko) | 2017-04-19 | 2024-05-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 조작된 항원 수용체를 발현하는 면역 세포 |
EP3645036A1 (en) | 2017-06-30 | 2020-05-06 | Cellectis | Cellular immunotherapy for repetitive administration |
KR20200055037A (ko) | 2017-09-19 | 2020-05-20 | 메사추세츠 인스티튜트 오브 테크놀로지 | 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도 |
JP2021501570A (ja) | 2017-10-18 | 2021-01-21 | ノバルティス アーゲー | 選択的タンパク質分解のための組成物及び方法 |
CN107880128B (zh) * | 2017-12-21 | 2021-03-02 | 常州费洛斯药业科技有限公司 | 一种抗cd19的全人源抗体或抗体片段及其方法和应用 |
US11779602B2 (en) | 2018-01-22 | 2023-10-10 | Endocyte, Inc. | Methods of use for CAR T cells |
CN110129369B (zh) * | 2018-02-09 | 2023-10-13 | 上海交通大学医学院附属上海儿童医学中心 | 一种嵌合抗原受体基因工程载体、免疫细胞及其应用 |
CN108715859B (zh) * | 2018-05-31 | 2021-08-03 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 靶向cd22的嵌合抗原受体及其应用 |
US11608382B2 (en) | 2018-06-13 | 2023-03-21 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
CN112739340A (zh) | 2018-07-23 | 2021-04-30 | 美真达治疗公司 | 抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
CN112771071A (zh) | 2018-09-28 | 2021-05-07 | 麻省理工学院 | 胶原蛋白定位的免疫调节分子及其方法 |
CN113195710A (zh) | 2018-12-06 | 2021-07-30 | 麒麟控股株式会社 | T细胞或nk细胞的制造方法、t细胞或nk细胞的培养用培养基、t细胞或nk细胞的培养方法、维持未分化t细胞的未分化状态的方法和t细胞或nk细胞的增殖促进剂 |
WO2020138371A1 (ja) | 2018-12-26 | 2020-07-02 | キリンホールディングス株式会社 | 改変tcr及びその製造方法 |
CN113661180A (zh) * | 2019-03-27 | 2021-11-16 | 宾夕法尼亚大学董事会 | Tn-MUC1嵌合抗原受体(CAR)T细胞疗法 |
WO2020263399A1 (en) | 2019-06-26 | 2020-12-30 | Massachusetts Institute Of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
JP2023503161A (ja) | 2019-11-26 | 2023-01-26 | ノバルティス アーゲー | Cd19及びcd22キメラ抗原受容体及びその使用 |
CN115698285A (zh) * | 2020-02-14 | 2023-02-03 | 小利兰·斯坦福大学董事会 | 具有cd2激活的嵌合抗原受体 |
JP2023517011A (ja) | 2020-03-05 | 2023-04-21 | ネオティーエックス セラピューティクス リミテッド | 免疫細胞を用いて癌を治療するための方法および組成物 |
BR112022018105A2 (pt) | 2020-03-10 | 2022-11-22 | Massachusetts Inst Technology | Métodos para gerar células nk tipo-memória modificadas e composições das mesmas |
US11896619B2 (en) | 2020-03-10 | 2024-02-13 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of NPM1c-positive cancer |
WO2021221783A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
US20210338833A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
WO2022086620A1 (en) * | 2020-10-20 | 2022-04-28 | The Methodist Hospital System | Psma-targeted immunotherapies for cancers |
WO2022087453A1 (en) * | 2020-10-22 | 2022-04-28 | Lyell Immunopharma, Inc. | Chimeric activation receptors |
EP4301782A1 (en) | 2021-03-05 | 2024-01-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
WO2022255489A1 (ja) | 2021-06-04 | 2022-12-08 | キリンホールディングス株式会社 | 細胞組成物、細胞組成物の製造方法及び細胞組成物を含む医薬組成物 |
JP2024531915A (ja) | 2021-08-05 | 2024-09-03 | ジーオー セラピューティクス,インコーポレイテッド | 抗グリコmuc抗体およびその使用 |
TW202325733A (zh) | 2021-09-03 | 2023-07-01 | 美商Go治療公司 | 抗醣化-lamp1抗體及其用途 |
TW202328188A (zh) | 2021-09-03 | 2023-07-16 | 美商Go治療公司 | 抗醣化-cmet抗體及其用途 |
WO2023064928A2 (en) | 2021-10-14 | 2023-04-20 | Arsenal Biosciences, Inc. | Immune cells having co-expressed shrnas and logic gate systems |
WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
WO2023217796A1 (en) * | 2022-05-10 | 2023-11-16 | Miltenyi Biotec B.V. & Co. KG | Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
US8211422B2 (en) * | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
US5993434A (en) | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US5712149A (en) * | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
GB9526131D0 (en) * | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
US6277368B1 (en) | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
US6678556B1 (en) | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
US7171264B1 (en) | 1999-05-10 | 2007-01-30 | Genetronics, Inc. | Intradermal delivery of active agents by needle-free injection and electroporation |
WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
ATE373078T1 (de) | 2000-02-24 | 2007-09-15 | Xcyte Therapies Inc | Gleichzeitige stimulation und konzentration von zellen |
AU2001245427A1 (en) | 2000-03-03 | 2001-09-17 | Valentis, Inc. | Nucleic acid formulations for gene delivery and methods of use |
AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
JP4448282B2 (ja) * | 2001-04-30 | 2010-04-07 | シティ・オブ・ホープ | ヒト癌を処置するのに有用なキメライムノレセプター |
US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
US20040014645A1 (en) | 2002-05-28 | 2004-01-22 | Advisys, Inc. | Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system |
US20050070841A1 (en) | 2002-07-04 | 2005-03-31 | Inovio As | Electroporation device and injection apparatus |
US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
US20050113564A1 (en) * | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
CA2568344C (en) | 2004-05-27 | 2016-01-19 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
AU2006342101A1 (en) | 2005-12-07 | 2007-10-25 | Genetronics, Inc | Variable volume electroporation chamber and methods therefore |
EP3006459B1 (en) * | 2008-08-26 | 2021-10-06 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
CA2776143A1 (en) * | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
DK2649086T3 (en) * | 2010-12-09 | 2017-09-18 | Univ Pennsylvania | USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER |
EA201490636A1 (ru) * | 2011-09-16 | 2014-08-29 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований |
IN2014DN06522A (el) * | 2012-02-22 | 2015-06-12 | Univ Pennsylvania | |
ES2816450T3 (es) * | 2012-02-22 | 2021-04-05 | Univ Pennsylvania | Uso de CAR basados en ICOS para mejorar la actividad antitumoral y la persistencia del CAR |
US9572836B2 (en) * | 2012-07-13 | 2017-02-21 | The Trustees Of The University Of Pennsylvania | Methods for assessing the suitability of transduced T cells for administration |
US9365641B2 (en) * | 2012-10-01 | 2016-06-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
NZ746914A (en) * | 2012-10-02 | 2020-03-27 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
CA2955154C (en) * | 2014-07-21 | 2023-10-31 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
WO2016028896A1 (en) * | 2014-08-19 | 2016-02-25 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
US10093746B2 (en) * | 2014-09-04 | 2018-10-09 | The Trustees Of The University Of Pennsylvania | Glypican-3 antibody and uses thereof |
WO2016090034A2 (en) * | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
MX2018010733A (es) * | 2016-03-04 | 2019-07-04 | Novartis Ag | Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas. |
WO2018026819A2 (en) * | 2016-08-01 | 2018-02-08 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
WO2019210207A2 (en) * | 2018-04-27 | 2019-10-31 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor t regulatory cells for the treatment of atherosclerosis |
US20210347851A1 (en) * | 2018-09-28 | 2021-11-11 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
EP3856779A1 (en) * | 2018-09-28 | 2021-08-04 | Novartis AG | Cd22 chimeric antigen receptor (car) therapies |
CA3124467A1 (en) * | 2018-12-19 | 2020-06-25 | The Trustees Of The University Of Pennsylvania | Use of cd2/5/7 knock-out anti-cd2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias |
CN113661180A (zh) * | 2019-03-27 | 2021-11-16 | 宾夕法尼亚大学董事会 | Tn-MUC1嵌合抗原受体(CAR)T细胞疗法 |
US20200370013A1 (en) * | 2019-05-20 | 2020-11-26 | The Trustees Of The University Of Pennsylvania | Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors |
-
2013
- 2013-02-22 IN IN6522DEN2014 patent/IN2014DN06522A/en unknown
- 2013-02-22 US US14/375,999 patent/US9783591B2/en active Active
- 2013-02-22 SG SG11201404284SA patent/SG11201404284SA/en unknown
- 2013-02-22 WO PCT/US2013/027361 patent/WO2013126729A1/en active Application Filing
- 2013-02-22 AU AU2013222284A patent/AU2013222284A1/en not_active Abandoned
- 2013-02-22 KR KR20147023594A patent/KR20140127829A/ko not_active Application Discontinuation
- 2013-02-22 CN CN201380010713.XA patent/CN104136458A/zh active Pending
- 2013-02-22 EA EA201491573A patent/EA201491573A1/ru unknown
- 2013-02-22 EP EP13751899.9A patent/EP2817331B1/en active Active
- 2013-02-22 EP EP23193203.9A patent/EP4275699A3/en active Pending
- 2013-02-22 BR BR112014020502A patent/BR112014020502A2/pt not_active IP Right Cessation
- 2013-02-22 ES ES13751899T patent/ES2959443T3/es active Active
- 2013-02-22 MX MX2014010185A patent/MX2014010185A/es unknown
- 2013-02-22 JP JP2014558875A patent/JP2015509716A/ja not_active Withdrawn
- 2013-02-22 CA CA2864489A patent/CA2864489C/en active Active
-
2014
- 2014-08-07 IL IL233993A patent/IL233993A0/en unknown
-
2017
- 2017-08-04 US US15/669,562 patent/US10501519B2/en active Active
-
2019
- 2019-07-02 US US16/460,221 patent/US11597754B2/en active Active
-
2021
- 2021-08-05 US US17/444,519 patent/US20210371495A1/en active Pending
-
2023
- 2023-02-17 US US18/170,695 patent/US20230242612A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20140127829A (ko) | 2014-11-04 |
EP2817331A4 (en) | 2015-09-30 |
US20230242612A1 (en) | 2023-08-03 |
MX2014010185A (es) | 2014-11-14 |
CA2864489A1 (en) | 2013-08-29 |
EP2817331A1 (en) | 2014-12-31 |
US20140370045A1 (en) | 2014-12-18 |
CN104136458A (zh) | 2014-11-05 |
EP4275699A3 (en) | 2024-01-03 |
AU2013222284A1 (en) | 2014-08-07 |
US10501519B2 (en) | 2019-12-10 |
CA2864489C (en) | 2023-08-08 |
US20210371495A1 (en) | 2021-12-02 |
SG11201404284SA (en) | 2014-10-30 |
IL233993A0 (en) | 2014-09-30 |
US20180037625A1 (en) | 2018-02-08 |
US9783591B2 (en) | 2017-10-10 |
US11597754B2 (en) | 2023-03-07 |
ES2959443T3 (es) | 2024-02-26 |
EP4275699A2 (en) | 2023-11-15 |
EA201491573A1 (ru) | 2015-03-31 |
EP2817331B1 (en) | 2023-08-30 |
BR112014020502A2 (pt) | 2019-09-24 |
WO2013126729A1 (en) | 2013-08-29 |
JP2015509716A (ja) | 2015-04-02 |
US20190352369A1 (en) | 2019-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN06522A (el) | ||
MX2020005143A (es) | Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer. | |
MX2018009820A (es) | Uso de cart19 para eliminar celulas b normales para inducir tolerancia. | |
IN2014DN07414A (el) | ||
IN2014DN11155A (el) | ||
MX2018006789A (es) | Receptores quimericos modificados y composiciones y metodos relacionados. | |
MX2018005618A (es) | Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados. | |
MX2020007021A (es) | Receptor quimerico de antigeno anti-cd19 humanizado. | |
MY185016A (en) | Progenitor cells of mesodermal lineage | |
MX2014010183A (es) | Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer. | |
MX2016008076A (es) | Receptores quimericos de antigeno de mesotelina humana y uso de los mismos. | |
MY190711A (en) | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor | |
EA201490636A1 (ru) | Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований | |
SG178991A1 (en) | Anti-gitr antibodies | |
MX369220B (es) | Moleculas que enlazan cd3 capaces de enlazar a cd3 humano y no humano. | |
CY1123467T1 (el) | Θεραπευτικο εμβολιο για τη θεραπεια του παιδικου διαβητη τυπου 1, εφαρμογη του κυτταροδιαχωριστη κυτταρομετριας ροης και της μεθοδου πολλαπλασιασμου των κυτταρων treg για την παραγωγη θεραπευτικου εμβολιου για τη θεραπεια του διαβητη τυπου 1 | |
GB2534478A (en) | Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10 | |
TN2013000246A1 (en) | Use of chimeric antigen receptor-modified t cells to treat cancer | |
MY171384A (en) | Composition and methods related to the prevention and treatment of rabies infection |